The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
CCH continues to expand its growth structure, after successful entrance to the Turkishmarket during 2006.The timing is right for Muslim business people to utilise the newlyavailable Shariah trade financing services now fueled by the vast cash resources which CCH can tap into in Bahrain A wholly owned subsidiary, CCH Central America Inc ('CCHCA'), announced today, it has been formed in Panama to provide trade finance facilities in the growing South American Market. http://lemminginvestor.intellicontact.com/test/update_cch_international2.html The initial focus will be on Peru, which the IMF reports as enjoying 8% growth, and is thus a substantial market for trade finance. Peru enjoys a strong economic relationship with the United States, its largest trading partner.....
Initial comment on the splendid result, at 07.00 this am, from one of our two greatest, early, ultra high growth discoveries of the year (the other need we say is Toledo Mining) PbT up 2% on accurate Ambrian forecast. Sales and profits up, as expected: Sales by x10, gross profit by x18 and Profit after Tax by an extraordinary x21 times The most important reassurance covers the main risk outstanding in January "whilst they will continue to seek improvements, this issue has now been largely resolved and that sawing efficiency is now in line with industry norms. There seems to be no indication of the savings generated, but they nust lead to increased margins for H1 '07 so that current extrapolations of capacity will IMO underestimate the coming profit levels.. Capacity increase by end 07 confirmed at 265MW therefore sales increase for FY '07 visible at 231%; and current PE of 33, but forward PE, (first crude estimate) reducing to x 14 times. Price Chart Comment This shows that the share price continues inside a modestly sloping six month trend channel at 123%/pa - a lower rate than during the price explosion of early Autumn but has gradually become oversold rather than overbought, which these results should reverse. Our short term target is 700p, which Mondays conference call fir analysts should help to drive. Over the next year there is still a x3 bagger to come.. http://lemminginvestor.intellicontact.com/test/update_renesola_comment3
The online entertainment market is experiencing massive growth, and Vividas has, today, at last landed the contract it deserves of 'significant value' against the technically far inferior technology of Microsoft Real Player and Adobe Flash. These have, nevertheless, through shows, presentations sales forces and much larger budgets, been able to swamp the market and till now win the large contracts as from the BBC, BT,etc from the still small but talented VDS sales team. Comment Inside www.lemminginvestor.com
Vey good report from www.lemminginvestor.com Very bullish in the long term. JORC agreement will see these fly.
Nick2412 - 4 Dec'06 - 08:57 - 12153 of 12175 Just thought I'd look at the debate on potential takeover prospects. As Lloyd Grossman might say, let's look at the clues ... 1) A remarkably specific post on iii saying something along the lines that several major pharmas and a VC had made approaches to look at the shareholder register. The post claimed the source was the company. The detail in the post gave it a ring of truth. Initially I dismissed the idea of it being linked to takeover prospects and thought, if accurate, it related to companies checking over BPRG for competitors etc. prior to signing on the dotted line with FMC. After all, the previous BPRG rns pushed BPRG more towards the definition of JV/partner. It's possible, but given BPRG's extremely protective role towards confidentiality why would they even hint at information if it were purely connected with FMC contracts? They wouldn't, as simple as that. So, if the story is accurate, the company has leaked the information out for a specific reason. They want everyone to know that they are under the microscope of some players who are eyeing them up for a takeover. At least if the news is out that will get the share price up and give some protection or enhance the resulting take out price. The weakness in the story is the notion of some highly secretive major pharmas in acquisitive mode approaching the company direct for a shareholder list. Not likely; there are other means of getting hold of on
according to www.lemminginvestor.com Former Lemming darling stock of 2003/04, Alizyme could be worth putting on your watch list after the company announced that its chief executive Richard Palmer, who has headed the small cap British drug developer for the last 10 years, has stepped down, and will be replaced by the company's finance head.
according to www.lemminginvestor.com Former Lemming darling stock of 2003/04, Alizyme could be worth putting on your watch list after the company announced that its chief executive Richard Palmer, who has headed the small cap British drug developer for the last 10 years, has stepped down, and will be replaced by the company's finance head.
Don't take my claim too flippantly that this is the Share of the Decade....... claimed now with a third trumpet blast...( Gilchrist take note) Can anyone provide evidence in the last ten years of faster sales and profit growth over seven successive quarters (including consensus estimates)than SOLA's trajectory to end Q2 '07. If anyone can, their nomination's candidacy will fall away with successive quarters. This whirlwind is set to continue at least until mid 2008. A poster today reminded us of SOLA's ambition to hit $2 bllion cap. To do that they need to post profits of $80,000,000. Until today they would have reached that level by H1 2008. Today's Press release implies that they will arrive 4-6 months earlier ar their target - soon after end 2007 This is the view of www.lemminginvestor.com
to be true? SOLA is a rare gift as a start-up - a derampers' death threat, which the Gadarene flock did not recognise precisely just because it is so rare. Candidates for admission are usually desperately undercapitalised, over borrowed, starved of working capital etc. SOLA was none of these - just desperate to stop turning good business away for lack of investment funds. Selling the founders' shares too early, too many, and too cheap, proved to have been a highly intelligent strategy. The 66% left with the original owners after Admission, is now worth far more and is far easier to access, than the original 100%. SOLA are earning heaps of cash from production operations - enough in Q3 and Q4 to pay for huge machinery investment programmes. Now the rate of growth decided on is too huge to continue entirely from internally generated cash. But that is normal. What was not normal was to generate so much cash that they COULD for a while sustain capital purchases out of profits and depreciation. It's a problem you or I would like to have.